RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0043-1768613
Synthesis and Crystal Structure Analysis of Histone Deacetylase Inhibitor Chidamide
Funding We gratefully acknowledge financial support from the National Science and Technology Major Project (Grant No. 2018ZX09711002-002-009), the National Natural Science Foundation of China (Grant No. 81703358), Science and Technology Commission of Shanghai Municipality (Grant No. 17431903900, 18QB1404200, 21S11908000, and 22ZR1460300), and Graduate Innovation Fund Project of China State Institute of Pharmaceutical Industry (Grant No. YJS2021013 and YJS2021011).
Abstract
Chidamide is the first oral subtype-selective histone deacetylase inhibitor approved in China for the treatment of relapsed and refractory peripheral T cell lymphoma. Due to the existence of isomers, many articles or patents have mistaken its structure. Herein we explored the synthesis of the key intermediate (E)-4-((3-(pyridin-3-yl)acrylamido)methyl)benzoic acid (A-3) and chidamide, using the condensing agent HBTU, instead of the unstable N,N'-carbonyldiimidazole. The single crystal of chidamide was determined by X-ray diffraction study. The optimized preparation process was easy to operate, and the purity of the final product can be up to 99.76%. Moreover, the structure of chidamide was established to be (E)-N-(2-amino-4-fluorophenyl)-4-((3-(pyridin-3-yl)acrylamido)methyl)benzamide.
# These authors contributed equally to this work.
Publikationsverlauf
Eingereicht: 03. September 2022
Angenommen: 31. März 2023
Artikel online veröffentlicht:
24. Mai 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Pan DS, Yang QJ, Fu X. et al. Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment. MedChemComm 2014; 5 (12) 1789-1796
- 2 Jiang Z, Li W, Hu X. et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20 (06) 806-815
- 3 Baldino CM, Muollo L, Warner JC. et al. Non-covalent derivatives and methods of treatment. WO Patent 2018222572 A1. December, 2018
- 4 Cuadrado T. María dM, García O, et al. Products for the treatment and prevention of neurological disorders coursing with a cognition deficit or impairment, and of neurodegenerative diseases. WO Patent 2016030345 A1. March, 2016
- 5 Chi LN, Yuan Y, Zhou FK. et al. Patent analysis of HDAC inhibitor chidamide [in Chinese]. Chin J New Drug 2020; 29 (01) 15-21
- 6 Liu L, Chen B, Qin S. et al. A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells. Biochem Biophys Res Commun 2010; 392 (02) 190-195
- 7 Nepali K, Chang TY, Lai MJ. et al. Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors. Eur J Med Chem 2020; 196: 112291
- 8 Singh A, Chang TY, Kaur N. et al. CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition. Eur J Med Chem 2021; 215: 113169
- 9 Wu YF, Ou CC, Chien PJ, Chang HY, Ko JL, Wang BY. Chidamide-induced ROS accumulation and miR-129-3p-dependent cell cycle arrest in non-small lung cancer cells. Phytomedicine 2019; 56: 94-102
- 10 Yuan XG, Huang YR, Yu T, Jiang HW, Xu Y, Zhao XY. Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner. Oncol Lett 2019; 18 (01) 411-419
- 11 Zhu X, Zhang J, Sun Y. et al. Restoration of miR-23a expression by chidamide sensitizes CML cells to imatinib treatment with concomitant downregulation of CRYAB. Bioengineered 2022; 13 (04) 8881-8892
- 12 Li JY, Xu WT, Zhuo R. et al. The research progress of chidamide antitumor mechanism [in Chinese]. Zhongliu Yaoxue 2019; 9 (01) 6-925
- 13 Yin ZH, Wu ZW, Lan YK. et al. Synthesis of chidamide, a new histone deacetylase (HDAC) inhibitor [in Chinese]. Chin J New Drug 2004; 13 (06) 536-538
- 14 Lu XP, Li ZB, Xu XK. E-configuration benzamide compound and pharmaceutical formulation and application thereof. WO Patent 2015149435 A1. October, 2015
- 15 Liu HZ, Ma JL, Guan CT, Guo M. A synthetic method of chidamide (in Chinese). CN Patent 105949114 A. September, 2016
- 16 Flick AC, Ding HX, Leverett CA. et al. Synthetic approaches to the 2014 new drugs. Bioorg Med Chem 2016; 24 (09) 1937-1980
- 17 Zhao JH, Hu H, Guan Y, Liao F, Yu XH. Process optimization of chidamide [in Chinese]. Carol J Pharm 2017; 48 (07) 994-996
- 18 Zhang LH, Zhu RY, Wei CF, Liu XT, Yu XH. Study on the synthetic process of chidamide [in Chinese]. Zhongguo Yaowu Huaxue Zazhi 2021; 31 (08) 589-592
- 19 Engstrom KM, Sheikh A, Ho R. et al. The stability of N,N-carbonyldiimidazole toward atmospheric moisture. Org Process Res Dev 2014; 18 (04) 488-494